OncoMatch/Clinical Trials/NCT07078500
Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
Is NCT07078500 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies orelabrutinib combined with the Pola-R-CHP regimen for diffuse large b-cell lymphoma (dlbcl).
Treatment: orelabrutinib combined with the Pola-R-CHP regimen — Assess the preliminary efficacy and safety of orelabrutinib in combination with the Pola-R-CHP regimen for the treatment of treatment-naive Non-GCB diffuse large B-cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Lab requirements
Blood counts
Neutrophils <1.5×10⁹/L; Platelets <75×10⁹/L [excluded]
Kidney function
Creatinine level more than 1.5 times the upper limit of normal [excluded]
Liver function
ALT or AST more than 2 times the upper limit of normal, ALP and bilirubin more than 1.5 times the upper limit of normal [excluded]
Laboratory values at screening (unless due to lymphoma): Neutrophils <1.5×10⁹/L; Platelets <75×10⁹/L; ALT or AST more than 2 times the upper limit of normal, ALP and bilirubin more than 1.5 times the upper limit of normal; Creatinine level more than 1.5 times the upper limit of normal.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07078500 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify